Trial Outcomes & Findings for A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis (NCT NCT06295692)

Last Updated: 2026-05-08

Results Overview

Percentage of participants with GPP who experienced treatment success at Week 16 was reported. Treatment success for GPP was defined as at least "minimally improved" rating in Clinical Global Impression (CGI) scale for GPP based on Japanese Dermatological Association (JDA) total score. JDA severity index includes skin symptoms (area of erythema with pustules, total area of erythema, and area of edema; each scored 0-3) and systemic/laboratory findings (fever, white blood cell count, C-reactive protein, and serum albumin; each scored 0-2). JDA total score was sum of 2 assessments ranging from 0 (best) to 17 (worst). CGI ratings were defined as: 1=Very much improved (greater than or equal to \[\>=\]3-point reduction in JDA total score), 2=Much improved (1-2-point reduction), 3=Minimally improved (no change in JDA total score, but \>=20 percent (%) reduction in area of erythema with pustules or meaningful improvement in \>=1 other parameter), 4=No change, 5=Worsened. Higher score = worsening.

Recruitment status

ACTIVE_NOT_RECRUITING

Study phase

PHASE3

Target enrollment

19 participants

Primary outcome timeframe

Week 16

Results posted on

2026-05-08

Participant Flow

The results presented are based on the primary completion date (14 Jan 2025). Remaining results will be reported within a year of study completion.

Participant milestones

Participant milestones
Measure	GPP: JNJ-77242113 200 mg QD Participants with generalized pustular psoriasis (GPP) received JNJ-77242113 200 milligrams (mg) tablet orally once daily (QD) from Week 0 up to Week 24.	EP: JNJ-77242113 200 mg QD Participants with erythrodermic psoriasis (EP) received JNJ-77242113 200 mg tablet orally QD from Week 0 up to Week 24.
Overall Study STARTED	9	10
Overall Study COMPLETED	1	1
Overall Study NOT COMPLETED	8	9

Reasons for withdrawal

Reasons for withdrawal
Measure	GPP: JNJ-77242113 200 mg QD Participants with generalized pustular psoriasis (GPP) received JNJ-77242113 200 milligrams (mg) tablet orally once daily (QD) from Week 0 up to Week 24.	EP: JNJ-77242113 200 mg QD Participants with erythrodermic psoriasis (EP) received JNJ-77242113 200 mg tablet orally QD from Week 0 up to Week 24.
Overall Study Ongoing	8	9

Baseline Characteristics

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	GPP: JNJ-77242113 200 mg QD n=9 Participants Participants with generalized pustular psoriasis (GPP) received JNJ-77242113 200 milligrams (mg) tablet orally once daily (QD) from Week 0 up to Week 24.	EP: JNJ-77242113 200 mg QD n=10 Participants Participants with erythrodermic psoriasis (EP) received JNJ-77242113 200 mg tablet orally QD from Week 0 up to Week 24.	Total n=19 Participants Total of all reporting groups
Age, Continuous	60 Years STANDARD_DEVIATION 11.91 • n=41 Participants	56.8 Years STANDARD_DEVIATION 14.01 • n=40 Participants	58.3 Years STANDARD_DEVIATION 12.8 • n=81 Participants
Sex: Female, Male Female	5 Participants n=41 Participants	1 Participants n=40 Participants	6 Participants n=81 Participants
Sex: Female, Male Male	4 Participants n=41 Participants	9 Participants n=40 Participants	13 Participants n=81 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=41 Participants	0 Participants n=40 Participants	0 Participants n=81 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	9 Participants n=41 Participants	10 Participants n=40 Participants	19 Participants n=81 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=41 Participants	0 Participants n=40 Participants	0 Participants n=81 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=41 Participants	0 Participants n=40 Participants	0 Participants n=81 Participants
Race (NIH/OMB) Asian	9 Participants n=41 Participants	10 Participants n=40 Participants	19 Participants n=81 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=41 Participants	0 Participants n=40 Participants	0 Participants n=81 Participants
Race (NIH/OMB) Black or African American	0 Participants n=41 Participants	0 Participants n=40 Participants	0 Participants n=81 Participants
Race (NIH/OMB) White	0 Participants n=41 Participants	0 Participants n=40 Participants	0 Participants n=81 Participants
Race (NIH/OMB) More than one race	0 Participants n=41 Participants	0 Participants n=40 Participants	0 Participants n=81 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=41 Participants	0 Participants n=40 Participants	0 Participants n=81 Participants
Region of Enrollment Japan	9 Participants n=41 Participants	10 Participants n=40 Participants	19 Participants n=81 Participants

PRIMARY outcome

Timeframe: Week 16

Population: Full analysis set (FAS) included all enrolled participants who received at least 1 dose of JNJ-77242113. This outcome measure was planned to be analyzed for specified arm only.

Outcome measures

Outcome measures
Measure	GPP: JNJ-77242113 200 mg QD n=9 Participants Participants with generalized pustular psoriasis (GPP) received JNJ-77242113 200 milligrams (mg) tablet orally once daily (QD) from Week 0 up to Week 24.
Percentage of Participants With Generalized Pustular Psoriasis (GPP) Who Experienced Treatment Success at Week 16	88.9 Percentage of participants Interval 51.8 to 99.7

PRIMARY outcome

Timeframe: Week 16

Population: FAS included all enrolled participants who received at least 1 dose of JNJ-77242113. This outcome measure was planned to be analyzed for specified arm only.

Percentage of participants with EP who experienced treatment success at Week 16 was reported. Treatment success for EP was defined as at least "minimally improved" rating in CGI scale for EP. The CGI scale is a clinician-rated 5-point scale with the following categories: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Worsened. Higher score indicated worsening.

Outcome measures

Outcome measures
Measure	GPP: JNJ-77242113 200 mg QD n=10 Participants Participants with generalized pustular psoriasis (GPP) received JNJ-77242113 200 milligrams (mg) tablet orally once daily (QD) from Week 0 up to Week 24.
Percentage of Participants With Erythrodermic Psoriasis (EP) Who Experience Treatment Success at Week 16	100.0 Percentage of participants Interval 69.2 to 100.0

Serious events: 2 serious events

Other events: 6 other events

Deaths: 0 deaths

EP: JNJ-77242113 200 mg QD

Serious events: 1 serious events

Other events: 8 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	GPP: JNJ-77242113 200 mg QD n=9 participants at risk Participants with generalized pustular psoriasis (GPP) received JNJ-77242113 200 milligrams (mg) tablet orally once daily (QD) from Week 0 up to Week 24.	EP: JNJ-77242113 200 mg QD n=10 participants at risk Participants with erythrodermic psoriasis (EP) received JNJ-77242113 200 mg tablet orally QD from Week 0 up to Week 24.
Blood and lymphatic system disorders Acquired Haemophilia	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Eye disorders Cataract	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.

Other adverse events

Additional Information

Global Medical Head Dermatology

Janssen Research and Development, LLC

Phone: 844-434-4210

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application.
Publication restrictions are in place

Restriction type: OTHER

Measure	GPP: JNJ-77242113 200 mg QD n=9 participants at risk Participants with generalized pustular psoriasis (GPP) received JNJ-77242113 200 milligrams (mg) tablet orally once daily (QD) from Week 0 up to Week 24.	EP: JNJ-77242113 200 mg QD n=10 participants at risk Participants with erythrodermic psoriasis (EP) received JNJ-77242113 200 mg tablet orally QD from Week 0 up to Week 24.
Infections and infestations Cystitis	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Gastrointestinal disorders Constipation	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Hepatobiliary disorders Hepatic Function Abnormal	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Infections and infestations Covid-19	0.00% 0/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Blood and lymphatic system disorders Eosinophilia	0.00% 0/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Eye disorders Keratitis	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Gastrointestinal disorders Angular Cheilitis	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Infections and infestations Hordeolum	0.00% 0/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Infections and infestations Influenza	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Infections and infestations Nasopharyngitis	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	20.0% 2/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Infections and infestations Oral Candidiasis	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Infections and infestations Pneumonia	0.00% 0/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Infections and infestations Suspected Covid-19	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Infections and infestations Upper Respiratory Tract Infection	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Infections and infestations Urinary Tract Infection	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Injury, poisoning and procedural complications Chillblains	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Injury, poisoning and procedural complications Rib Fracture	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Investigations Blood Lactate Dehydrogenase Increased	0.00% 0/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Metabolism and nutrition disorders Diabetes Mellitus	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Metabolism and nutrition disorders Dyslipidaemia	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Musculoskeletal and connective tissue disorders Arthralgia	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Musculoskeletal and connective tissue disorders Back Pain	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Musculoskeletal and connective tissue disorders Pain in Extremity	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Nervous system disorders Carotid Arteriosclerosis	0.00% 0/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Nervous system disorders Dizziness Postural	0.00% 0/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Psychiatric disorders Depression	0.00% 0/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Skin and subcutaneous tissue disorders Eczema Asteatotic	0.00% 0/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Skin and subcutaneous tissue disorders Erythrodermic Psoriasis	0.00% 0/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Skin and subcutaneous tissue disorders Hyperkeratosis	0.00% 0/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Skin and subcutaneous tissue disorders Mechanical Urticaria	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Skin and subcutaneous tissue disorders Pruritus	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	10.0% 1/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.
Vascular disorders Hypertension	11.1% 1/9 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.	0.00% 0/10 • From Week 0 up to Week 24 Safety analysis set included all enrolled participants who received at least 1 dose of JNJ-77242113.